{
  "id": 7893857,
  "title": "Alignment healthcare CEO John Kao sells $356,200 in ALHC stock",
  "url": "https://urgent.news/2026/09/16/alignment-healthcare-ceo-john-kao-sells-356-200-in-alhc-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T23:15:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alignment-healthcare-ceo-john-kao-sells-356200-in-alhc-stock-93CH-4904681"
  },
  "original_language": "en",
  "account": "Alignment Healthcare CEO John E. Kao recently disposed of 27,400 shares of the company's common stock on September 14, 2026, amounting to a total of $356,200. This sale was carried out under a pre-established Rule 10b5-1 trading plan, which Kao had put in place on May 27, 2026. Post the sale, Kao currently owns 1,223,473 shares of common stock, with an additional 590,766 shares indirectly held through his JEK Trust. Interestingly, the timing of this transaction is noteworthy given the recent sharp decline in ALHC shares, which are now trading at $8.71, a 33% drop from the $13.00 he sold them for. Analysts, as per InvestingPro, suggest the stock is undervalued at present, trading near its 52-week low of $8.52. For those interested in a more detailed analysis, 14 additional ProTips and a thorough Fair Value assessment are available on the platform. Furthermore, Alignment Healthcare's most recent quarterly earnings report for Q2 2026 exceeded expectations, with an adjusted earnings per share of $0.17, beating the estimated $0.13. However, revenue fell short of projections, reporting $1.3 billion against a projected $1.31 billion. Despite a 31% growth in membership and a 48% boost in adjusted EBITDA to $68 million, the stock experienced a decline in after-hours trading. The company also raised its full-year 2026 earnings guidance for membership, revenue, gross profit, and EBITDA. On the analyst front, TD Cowen has maintained a Buy rating on Alignment Healthcare, with a price target of $21, despite facing third-quarter challenges related to acute hospital billing and skilled nursing facilities. Conversely, Raymond James has downgraded the stock to Outperform from Strong Buy, arguing for increased uncertainty in earnings as the firm broadens its reach beyond California. Analyst John Ransom from Raymond James acknowledged the company’s steady performance but cautioned about the hurdles in forecasting earnings due to heightened investment expenditures. These updates paint a picture of a mixed outlook among analysts regarding Alignment Healthcare's future trajectory.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "BillionToOne CEO Oguzhan Atay sells $2.5m in company stock",
        "url": "https://urgent.news/2026/09/17/billiontoone-ceo-oguzhan-atay-sells-2-5m-in-company-stock",
        "published": "2026-09-17T00:01:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}